Table 1. Open in new tab Top potential...

Table 1.

Top potential SLIs

Pair	Cancer type	Driver’s freq	P-value	DD	Pathway	Validation
TP53–TXNRD1	Liver cancer	30.8%	.014	0.94	0.58	Yes
KDM6A–CCND1	Bladder cancer	25.2%	.004	0.76	0.54	Yes
SMAD4–SLC7A1	Pancreatic cancer	22.4%	.003	0.68	0.44	No
MUC16–FDPS	Lung cancer	40.7%	.013	0.52	0.50	No
RB1–PAICS	Bladder cancer	16.9%	.049	0.48	0.52	No
RYR2–CCND1	Lung cancer	38.9%	.008	0.55	0.41	No
RB1–AHR	Bladder cancer	16.9%	.019	0.46	0.44	Yes
RB1–CDK2	Bladder cancer	16.9%	.005	0.42	0.41	Yes
KMT2D–OAZ1	Lymphoma	29.8%	.018	0.41	0.42	No

Pair	Cancer type	Driver’s freq	P-value	DD	Pathway	Validation
TP53–TXNRD1	Liver cancer	30.8%	.014	0.94	0.58	Yes
KDM6A–CCND1	Bladder cancer	25.2%	.004	0.76	0.54	Yes
SMAD4–SLC7A1	Pancreatic cancer	22.4%	.003	0.68	0.44	No
MUC16–FDPS	Lung cancer	40.7%	.013	0.52	0.50	No
RB1–PAICS	Bladder cancer	16.9%	.049	0.48	0.52	No
RYR2–CCND1	Lung cancer	38.9%	.008	0.55	0.41	No
RB1–AHR	Bladder cancer	16.9%	.019	0.46	0.44	Yes
RB1–CDK2	Bladder cancer	16.9%	.005	0.42	0.41	Yes
KMT2D–OAZ1	Lymphoma	29.8%	.018	0.41	0.42	No

Top SLIs from our analysis are presented, including DD scores and pathway scores. Validation indicates interactions with experimental evidence in STRING-db. SLIs presented have DD > 0.4 and pathway score >0.4, ordered by the sum of both.

This Feature Is Available To Subscribers Only